BioSyent Inc. (CVE:RX - Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$11.26 and traded as low as C$11.03. BioSyent shares last traded at C$11.05, with a volume of 2,810 shares trading hands.
BioSyent Price Performance
The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90. The business's 50-day simple moving average is C$11.25 and its 200 day simple moving average is C$10.99. The firm has a market capitalization of C$125.81 million, a P/E ratio of 17.85 and a beta of 0.93.
Insider Buying and Selling at BioSyent
In other news, insider FAX Capital Corp. sold 230,800 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total value of C$2,566,496.00. Also, Senior Officer Robert Joseph March sold 4,775 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total transaction of C$55,628.75. Insiders have sold 349,144 shares of company stock worth $3,903,370 over the last ninety days. Insiders own 33.65% of the company's stock.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Further Reading
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
